Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Ernstoff

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Blood|January 19, 2008
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccinesCory L Ahonen, Anna Wasiuk, Shinichiro Fuse, et al.
Melanoma Research|July 6, 2018
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristicsIvan Gorlov, Irene Orlow, Carol Ringelberg, et al.
Cancer Immunology Research|July 26, 2019
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and ImmunosuppressionWenwen Xu, Juan Dong, Yongwei Zheng, et al.
Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Cancers|August 14, 2025
Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV BiomarkersShin-La Shu, Shawna Benjamin-Davalos, Xue Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 16, 2011
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumorsJeffrey S Weber, Nicholas J Vogelzang, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)David H Lawson, Sandra Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Plos One|December 11, 2012
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccineBenita Wolf, Adrian Schwarzer, Anik L Côté, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Blood|January 19, 2008
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccinesCory L Ahonen, Anna Wasiuk, Shinichiro Fuse, et al.
Melanoma Research|July 6, 2018
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristicsIvan Gorlov, Irene Orlow, Carol Ringelberg, et al.
Cancer Immunology Research|July 26, 2019
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and ImmunosuppressionWenwen Xu, Juan Dong, Yongwei Zheng, et al.
Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Cancers|August 14, 2025
Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV BiomarkersShin-La Shu, Shawna Benjamin-Davalos, Xue Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 16, 2011
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumorsJeffrey S Weber, Nicholas J Vogelzang, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)David H Lawson, Sandra Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Plos One|December 11, 2012
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccineBenita Wolf, Adrian Schwarzer, Anik L Côté, et al.
Pageof 17